Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discovery and characterization of the tuberculosis drug lead ecumicin.

Literature DB >> 25409285

Discovery and characterization of the tuberculosis drug lead ecumicin.

Wei Gao^1,2, Jin-Yong Kim^3,4, Shao-Nong Chen¹, Sang-Hyun Cho², Jongkeun Choi⁵, Birgit U Jaki^1,2, Ying-Yu Jin⁴, David C Lankin¹, Ji-Ean Lee⁴, Sun-Young Lee^3,4, James B McAlpine^1,2, José G Napolitano¹, Scott G Franzblau², Joo-Won Suh^3,4, Guido F Pauli^1,2.

Abstract

The new tuberculosis (TB) lead ecumicin (1), a cyclic tridecapeptide, was isolated from Nonomuraea sp. MJM5123, following a high-throughput campaign for anti-TB activity. The large molecular weight of 1599 amu detected by LC-HR-MS precluded the initial inference of its molecular formula. The individual building blocks were identified by extensive NMR experiments. The resulting two possible planar structures were distinguished by LC-MS(2). Determination of absolute configuration and unambiguous structural confirmation were carried out by X-ray crystallography and Marfey's analysis.

Entities: CellLine Chemical Disease Species

Mesh：

Substances：

Year: 2014 PMID： 25409285 PMCID： PMC5450905 DOI： 10.1021/ol5026603

Source DB: PubMed Journal: Org Lett ISSN： 1523-7052 Impact factor: 6.005

11 in total

Review 1. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

Authors: Christian Lienhardt; Mario Raviglione; Mel Spigelman; Richard Hafner; Ernesto Jaramillo; Michael Hoelscher; Alimuddin Zumla; Jan Gheuens
Journal: J Infect Dis Date: 2012-03-22 Impact factor: 5.226

Review 2. Use of Marfey's reagent and analogs for chiral amino acid analysis: assessment and applications to natural products and biological systems.

Authors: R Bhushan; H Brückner
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-06-17 Impact factor: 3.205

3. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.

Authors: Kanakeshwari Falzari; Zhaohai Zhu; Dahua Pan; Huiwen Liu; Poonpilas Hongmanee; Scott G Franzblau
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

4. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors: L Collins; S G Franzblau
Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191

5. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.

Authors: Wei Gao; Jin-Yong Kim; Jeffrey R Anderson; Tatos Akopian; Seungpyo Hong; Ying-Yu Jin; Olga Kandror; Jong-Woo Kim; In-Ae Lee; Sun-Young Lee; James B McAlpine; Surafel Mulugeta; Suhair Sunoqrot; Yuehong Wang; Seung-Hwan Yang; Tae-Mi Yoon; Alfred L Goldberg; Guido F Pauli; Joo-Won Suh; Scott G Franzblau; Sanghyun Cho
Journal: Antimicrob Agents Chemother Date: 2014-11-24 Impact factor: 5.191

6. Antimycobacterial cycloartanes from Borrichia frutescens.

Authors: C L Cantrell; T Lu; F R Fronczek; N H Fischer; L B Adams; S G Franzblau
Journal: J Nat Prod Date: 1996-12 Impact factor: 4.050

Review 7. Quantitative 1H NMR. Development and potential of an analytical method: an update.

Authors: Guido F Pauli; Tanja Gödecke; Birgit U Jaki; David C Lankin
Journal: J Nat Prod Date: 2012-04-06 Impact factor: 4.050

8. Agelasine F from a Philippine Agelas sp. sponge exhibits in vitro antituberculosis activity.

Authors: G C Mangalindan; M T Talaue; L J Cruz; S G Franzblau; L B Adams; A D Richardson; C M Ireland; G P Concepcion
Journal: Planta Med Date: 2000-05 Impact factor: 3.352

9. Ohmyungsamycins A and B: cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp. from a volcanic island.

Authors: Soohyun Um; Tae Joon Choi; Heegyu Kim; Byung Yong Kim; Seong-Hwan Kim; Sang Kook Lee; Ki-Bong Oh; Jongheon Shin; Dong-Chan Oh
Journal: J Org Chem Date: 2013-11-26 Impact factor: 4.354

10. Enhanced 13C resolution in semi-selective HMbC: a band-selective, constant-time HMBC for complex organic structure elucidation by NMR.

Authors: Tim D W Claridge; Ignacio Pérez-Victoria
Journal: Org Biomol Chem Date: 2003-11-07 Impact factor: 3.876

16 in total

Review 1. Natural products as probes in pharmaceutical research.

Authors: Esther K Schmitt; D Hoepfner; P Krastel
Journal: J Ind Microbiol Biotechnol Date: 2015-10-05 Impact factor: 3.346

Review 2. Discovery of novel drug targets and their functions using phenotypic screening of natural products.

Authors: Junghwa Chang; Ho Jeong Kwon
Journal: J Ind Microbiol Biotechnol Date: 2015-09-12 Impact factor: 3.346

3. Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease.

Authors: Kirsten Famulla; Peter Sass; Imran Malik; Tatos Akopian; Olga Kandror; Marina Alber; Berthold Hinzen; Helga Ruebsamen-Schaeff; Rainer Kalscheuer; Alfred L Goldberg; Heike Brötz-Oesterhelt
Journal: Mol Microbiol Date: 2016-04-01 Impact factor: 3.501

4. Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources.

Authors: Edyta M Grzelak; Changhwa Hwang; Geping Cai; Joo-Won Nam; Mary P Choules; Wei Gao; David C Lankin; James B McAlpine; Surafel G Mulugeta; José G Napolitano; Joo-Won Suh; Seung Hwan Yang; Jinhua Cheng; Hanki Lee; Jin-Yong Kim; Sang-Hyun Cho; Guido F Pauli; Scott G Franzblau; Birgit U Jaki
Journal: ACS Infect Dis Date: 2016-02-23 Impact factor: 5.084

5. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.

6. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.

Authors: Nina M Wolf; Hyun Lee; Mary P Choules; Guido F Pauli; Rasika Phansalkar; Jeffrey R Anderson; Wei Gao; Jinhong Ren; Bernard D Santarsiero; Hanki Lee; Jinhua Cheng; Ying-Yu Jin; Ngoc Anh Ho; Nguyen Minh Duc; Joo-Won Suh; Celerino Abad-Zapatero; Sanghyun Cho
Journal: ACS Infect Dis Date: 2019-05-03 Impact factor: 5.084

Discovery and characterization of the tuberculosis drug lead ecumicin.

Review 1. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

Review 2. Use of Marfey's reagent and analogs for chiral amino acid analysis: assessment and applications to natural products and biological systems.

3. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.

4. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

5. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.

6. Antimycobacterial cycloartanes from Borrichia frutescens.

Review 7. Quantitative 1H NMR. Development and potential of an analytical method: an update.

8. Agelasine F from a Philippine Agelas sp. sponge exhibits in vitro antituberculosis activity.

9. Ohmyungsamycins A and B: cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp. from a volcanic island.

10. Enhanced 13C resolution in semi-selective HMbC: a band-selective, constant-time HMBC for complex organic structure elucidation by NMR.

Review 1. Natural products as probes in pharmaceutical research.

Review 2. Discovery of novel drug targets and their functions using phenotypic screening of natural products.

3. Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease.

4. Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources.

5. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.

6. High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.

Review 7. Using chemical inhibitors to probe AAA protein conformational dynamics and cellular functions.

8. Computer-assisted ¹ H NMR analysis of the anti-tuberculosis drug lead ecumicin.

9. Improvement of the productivity of ecumicin, a novel anti-tuberculosis agent, from new Nonomuraea sp. MJM5123.

Review 10. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.